-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Emergent BioSolutions Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2011 to Q1 2022.
- Emergent BioSolutions Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2022 was $1.9M.
- Emergent BioSolutions Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$7.3M, a 78.3% increase from 2022.
- Emergent BioSolutions Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$33.7M, a 178% decline from 2021.
- Emergent BioSolutions Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $43M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)